Brainstorm Cell Therapuetics Inc. Daily Stock Analysis

Daily Stock Analysis, BCLI, Brainstorm Cell Therapuetics Inc, priceseries

Brainstorm Cell Therapuetics Inc. Daily Stock Analysis
Stock Information
Open
2.95
Close
2.92
High
2.98
Low
2.90
Previous Close
2.96
Daily Price Gain
-0.04
YTD High
4.21
YTD High Date
Jan 3, 2022
YTD Low
2.75
YTD Low Date
Jan 24, 2022
YTD Price Change
-1.27
YTD Gain
-30.31%
52 Week High
4.75
52 Week High Date
Mar 24, 2021
52 Week Low
2.75
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-0.54
52 Week Gain
-15.61%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
2.84
Feb 24. 2017
3.60
17 Trading Days
26.69%
Link
LONG
May 11. 2018
3.64
Jun 7. 2018
4.66
18 Trading Days
27.90%
Link
LONG
Jun 17. 2019
3.69
Jul 16. 2019
4.17
20 Trading Days
13.08%
Link
LONG
Dec 24. 2019
3.95
Jan 21. 2020
4.32
17 Trading Days
9.43%
Link
LONG
Feb 11. 2020
4.67
Feb 27. 2020
6.36
11 Trading Days
36.26%
Link
LONG
Mar 4. 2020
6.96
Mar 9. 2020
7.36
3 Trading Days
5.71%
Link
LONG
Apr 6. 2020
4.81
May 7. 2020
6.23
22 Trading Days
29.51%
Link
LONG
May 29. 2020
7.45
Jul 28. 2020
14.96
41 Trading Days
100.76%
Link
LONG
Sep 8. 2020
13.02
Sep 23. 2020
14.21
11 Trading Days
9.13%
Link
LONG
Jan 14. 2021
5.01
Feb 1. 2021
5.55
11 Trading Days
10.72%
Link
LONG
Feb 2. 2021
5.87
Feb 18. 2021
6.73
11 Trading Days
14.58%
Link
Company Information
Stock Symbol
BCLI
Exchange
NasdaqCM
Company URL
http://www.brainstorm-cell.com
Company Phone
201-488-0460
CEO
Chaim Lebovits
Headquarters
New Jersey
Business Address
3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK, NJ 07601
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001137883
About

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops innovative adult stem cell therapeutic products. It currently focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in Hackensack, NJ.

Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading